Rexahn Pharmaceuticals, Inc. (NYSE: RNN) announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO) covering RX-21101 for the targeted delivery of docetaxel directly into cancer tumor cells using a nano-polymer conjugate technology.
{iframe}http://www.streetinsider.com/Corporate+News/Rexahn+Pharma+%28RNN%29+Announces+Receipt+of+U.S.+Patent+Related+to+RX-21101/12168394.html{/iframe}